Get the Stockscreener App
66.66
0.16%
0.19
Edwards Lifesciences Corp stock is traded at $66.66, with a volume of 1.57M.
It is up +0.16% in the last 24 hours and up +1.66% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
See More
Previous Close:
$66.47
Open:
$66.17
24h Volume:
1.57M
Relative Volume:
0.26
Market Cap:
$40.04B
Revenue:
$5.87B
Net Income/Loss:
$4.16B
P/E Ratio:
28.49
EPS:
2.34
Net Cash Flow:
$551.80M
1W Performance:
-4.03%
1M Performance:
+1.66%
6M Performance:
-21.91%
1Y Performance:
-0.74%
1-Day Range:
$65.51
$66.67
1-Week Range:
$65.51
$70.65
52-Week Range:
$58.93
$96.12
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Kessler Topaz Meltzer & Check, LLP Reminds EW Investors of December 13, 2024 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact the Firm - GlobeNewswire Inc.
EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
EW LAWSUIT ALERT: BFA Law Announces Edwards Lifesciences has been Sued for Securities Fraud and Urges Investors to Contact the Firm by December 13 Deadline - Newsfile
EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit with the Schall Law Firm - Marketscreener.com
EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: - GlobeNewswire
The Gross Law Firm Notifies Edwards Lifesciences Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineEW - Marketscreener.com
TOP RANKED ROSEN LAW FIRM Encourages Edwards Lifesciences Corporation Investors to Secure - The Bakersfield Californian
TOP RANKED ROSEN LAW FIRM Encourages Edwards Lifesciences - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation - Marketscreener.com
EW INVESTOR DEADLINE: Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - AccessWire
BFA Law Announces EDWARDS LIFESCIENCES Has Been Sued for Securities Fraud and Urges Investors Who Suffered Losses to Contact the Firm Before Upcoming Court Deadline - Newsfile
Kessler Topaz Meltzer & Check, LLP Encourages Edwards Lifesciences Corporation Investors with Losses to Contact the Firm - Markets Insider
New York State Common Retirement Fund Sells 63,711 Shares of Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
EW LAWSUIT REPORT: Edwards Lifesciences Investors that Lost Money are Alerted to Contact BFA Law by December 13 Class Action Deadline - Newsfile
Edwards Lifesciences Corporation (EW) Fell Due to Missed Earnings Expectations and Weak Guidance - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Cut to "Hold" at Daiwa America - MarketBeat
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation - Markets Insider
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
EW CLASS ACTION NEWS: Edwards Lifesciences Investors are Urged to Contact BFA Law before December 13 Court Deadline in Securities Fraud Case after 31% Stock Drop - Newsfile
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
Shareholders that lost money on Edwards Lifesciences Corporation(EW) should contact The Gross Law Firm about pending Class ActionEW - Marketscreener.com
Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation - BioSpace
Edwards Lifesciences Corporation (EW) Investors: December 13, 2024 Filing Deadline in Securities Class Action - GlobeNewswire Inc.
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
BofA maintains $75 target on Edwards Lifesciences shares - Investing.com
Goldman Sachs maintains $80 target on Edwards Lifesciences stock - Investing.com
Edwards Lifesciences (NYSE:EW) Raised to Hold at Sanford C. Bernstein - MarketBeat
BFA Law Notifies EDWARDS LIFESCIENCES (EW) Investors to Contact the Firm by December 13 Class Action Deadline after Stock Drops 31% - Newsfile
abrdn plc Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
JPMorgan views Edwards Lifesciences TAVR data positively - Yahoo Finance
Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Investors of Important Deadline in Securities Fraud Class Action Lawsuit - Marketscreener.com
Farmers & Merchants Investments Inc. Has $7.32 Million Stake in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Edwards Lifesciences Co. (NYSE:EW) Sees Significant Decline in Short Interest - MarketBeat
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
EW INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
TD Cowen holds Edwards Lifesciences at $70 target - Investing.com
Bernstein Lifts Edwards Lifesciences Rating, Sees Balanced Risk-Reward in Tavr Market - Yahoo Finance UK
Edwards Lifesciences' SWOT analysis: stock faces TAVR headwinds, TMTT promise - Investing.com
Edwards Lifesciences upgraded to outperform by Bernstein - MSN
International Markets and Edwards Lifesciences (EW): A Deep Dive for Investors - Yahoo Finance
EW FRAUD NOTICE: Edwards Lifesciences Investors are Urged to Contact BFA Law before Expiration of Upcoming December 13 Legal Deadline in Securities Fraud Class Action - Newsfile
EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Edwards Lifesciences Corporation(EW) of a Class Action Lawsuit and an Upcoming Deadline - Marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Edwards - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors to - The Bakersfield Californian
Edwards Lifesciences Co. (NYSE:EW) Stock Position Increased by DekaBank Deutsche Girozentrale - MarketBeat
First Bank & Trust Has $798,000 Position in Edwards Lifesciences Co. (NYSE:EW) - MarketBeat
Earnings Beat: Edwards Lifesciences Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Edwards Lifesciences Corporation (NYSE:EW) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Edwards Lifesciences reports robust third-quarter growth By Investing.com - Investing.com Australia
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):